



1625
Jf

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,134-E)

In the Application of:

Jun Yuan et al.

U.S Application No.: 09/914,957

Filed: January 22, 2002

For: Aryl Fused 2,4-Disubstituted Pyridines:
NK3 Receptor Ligands

)
) Examiner: E. Huang

)
) Group Art: 1625

)
)
)
) Confirmation No. 6627

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

In regard to the above identified application:

1. We are transmitting herewith the attached:

- a. Response to the Restriction Requirement Mailed May 14, 2004; and
- b. Postcard.

2. With respect to additional fees:


A. Attached are checks in the amount of \$.

B. Charge the total additional fee to our Deposit Account No. 13-2490.
A duplicate copy of this sheet is enclosed.

3. Please charge any additional fees or credit overpayment to Deposit Account No.13-2490. A duplicate copy of this sheet is enclosed.

4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450 on this 14th day of June, 2004.

By :


Steven J. Sarussi
Reg. No. 32,784

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001



Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,

on June 14, 2004 (Date of Deposit).

6/14/04
Date

[Signature]
Name

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Attorney Docket No.: 99-134-E)

In re Application of:

Jun Yuan et al.

Serial No.: 09/914,957

Filed: January 22, 2002

For: Aryl Fused 2,4-

Disubstituted Pyridines:

NK3 Receptor Ligands

Before the Examiner:

Huang, Evelyn Mei

Art Unit: 1625

RESPONSE TO THE RESTRICTION REQUIREMENT

MAILED MAY 14, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Responsive to the Restriction Requirement mailed May 14, 2004, Applicants elect the claims of Group I, i.e., claims 4-6, 9-19, and 1, 30-39 in part. With respect to the requirement that Applicants elect a single disease as a species, Applicants elect schizophrenia.

The Listing of Claims begins on page 3 of this paper.

Remarks begin on page 11 of this paper.